Siplizumab ELISA Kit

Catalog No.

KDC20801

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.125 - 5,000 ng/mL

Sensitivity

33.12 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

MEDI-507, CAS: 288392-69-8

Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro., PMID:37270108

Distinct association between chronic Epstein-Barr virus infection and T cell compartments from pediatric heart, kidney, and liver transplant recipients., PMID:37187296

Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281

Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity., PMID:33643309

Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro., PMID:33262770

CD2 Immunobiology., PMID:32582179

Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody., PMID:31630416

Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro., PMID:31319439

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas., PMID:29032710

Novel and emerging drugs for rarer chronic lymphoid leukaemias., PMID:22483155

Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies., PMID:20618506

Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients., PMID:19917362

Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease., PMID:19671093

Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease., PMID:19623014

Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab., PMID:19471949

EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies., PMID:19293260

Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine., PMID:17588483

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma., PMID:17335294

The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion., PMID:15544625

Gateways to clinical trials., PMID:12949633

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507., PMID:12649132

Gateways to clinical trials., PMID:12224444

Document Download

Siplizumab ELISA Kit.pdf